title: Impact of timing on efficacy and safetyof intracoronary autologous bone marrow stem cells transplantation in acute myocardial infarction: a pooled subgroup analysis of randomized controlled trials.
abstract: BACKGROUND
  Until now there were no clinical studies or systematic reviews to investigate the impact of timing on efficacy and safety of intracoronary bone marrow stem cell (BMSC) transfer in patients with acute myocardial infarction (AMI).
  
  
  OBJECTIVE
  Timing of BMSC administration might play an important role in the therapeutic response in AMI patients.
  
  
  METHODS
  A systematic literature search of PubMed, MEDLINE, and Cochrane Evidence-Based Medicine (EBM) databases was made on randomized controlled trials with at least 3-month follow-up data for patients with AMI undergoing emergent percutaneous coronary intervention (PCI) and receiving intracoronary BMSC transfer thereafter.
  
  
  RESULTS
  A total of 7 trials with 660 patients were available for analysis. Compared to baseline level, BMSC transfer at 4 to 7 days post-AMI significantly improved left ventricular ejection fraction (LVEF; 4.63% increase, 95% confidence interval [CI]: 1.00%-8.26%, P = 0.01), reduced left ventricular (LV) end-systolic dimensions (95% CI: - 0.53 - 0.02, P = 0.03), decreased the incidences of revascularization (odds ratio [OR]: 0.60, 95% CI: 0.37-0.97, P = 0.04), decreased the cumulative clinical events of death or recurrent myocardial infarction (OR: 0.32, 95% CI: 0.11-0.95, P = 0.04), and decreased culprit artery restenosis or ventricular arrhythmia (OR: 0.59, 95% CI: 0.36-0.96, P = 0.03) however these improvements did not reach statistical significance in emergent transfer trials (within 24 hour post-AMI). Compared with emergent transfer, intracoronary BMSC therapy at 4 to 7 days also significantly reduced the incidence of revascularization (P for interaction = 0.02).
  
  
  CONCLUSIONS
  BMSC transfer at 4 to 7 days post-AMI was superior to that within 24 hours in improving LVEF, decreasing LV end-systolic dimensions, and reducing the incidence of revascularization.
authors.affiliation: Shanghai Institute of Cardiovascular Diseases, Zhongshan Hospital, Fudan University, Shanghai, China.
authors.forename: Shuning
authors.initials: S
authors.lastname: Zhang
authors.forename: Aijun
authors.initials: A
authors.lastname: Sun
authors.forename: Danling
authors.initials: D
authors.lastname: Xu
authors.forename: Kang
authors.initials: K
authors.lastname: Yao
authors.forename: Zheyong
authors.initials: Z
authors.lastname: Huang
authors.forename: Huan
authors.initials: H
authors.lastname: Jin
authors.forename: Keqiang
authors.initials: K
authors.lastname: Wang
authors.forename: Yunzeng
authors.initials: Y
authors.lastname: Zou
authors.forename: Junbo
authors.initials: J
authors.lastname: Ge
mesh_terms: D015906:Angioplasty, Balloon, Coronary / Q000009:adverse effects / Q000401:mortality; D001145:Arrhythmias, Cardiac / Q000209:etiology; D016026:Bone Marrow Transplantation / Q000009:adverse effects / Q000401:mortality; D003131:Combined Modality Therapy; D023903:Coronary Restenosis / Q000209:etiology; D005260:Female; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000401:mortality / Q000503:physiopathology / Q000601:surgery / Q000628:therapy*; D016017:Odds Ratio; D017594:Publication Bias; D016032:Randomized Controlled Trials as Topic; D020127:Recovery of Function; D012008:Recurrence; D015203:Reproducibility of Results; D018570:Risk Assessment; D013318:Stroke Volume; D013927:Thrombosis / Q000209:etiology; D013997:Time Factors; D014182:Transplantation, Autologous; D016896:Treatment Outcome; D016277:Ventricular Function, Left
references.citation: Cardiovasc Res. 2002 Aug 1;55(2):329-40
references.pmid: 12123772
references.citation: Lancet. 2004 Mar 6;363(9411):751-6
references.pmid: 15016484
references.citation: Circulation. 2006 Mar 14;113(10):1287-94
references.pmid: 16520413
references.citation: Control Clin Trials. 1996 Feb;17(1):1-12
references.pmid: 8721797
references.citation: Nat Med. 2001 Apr;7(4):430-6
references.pmid: 11283669
references.citation: Heart. 2006 Dec;92(12):1764-7
references.pmid: 16775089
references.citation: Zhonghua Xin Xue Guan Bing Za Zhi. 2006 Jul;34(7):577-81
references.pmid: 17081355
references.citation: Circulation. 2001 Feb 6;103(5):634-7
references.pmid: 11156872
references.citation: Lancet. 2006 Jan 14;367(9505):113-21
references.pmid: 16413875
references.citation: Arterioscler Thromb Vasc Biol. 1996 Jan;16(1):44-50
references.pmid: 8548425
references.citation: N Engl J Med. 2006 Sep 21;355(12):1199-209
references.pmid: 16990383
references.citation: Circulation. 2007 Jul 24;116(4):366-74
references.pmid: 17620510
references.citation: J Am Coll Cardiol. 2006 Apr 18;47(8):1727-30
references.pmid: 16631016
references.citation: J Am Coll Cardiol. 2007 Feb 20;49(7):741-52
references.pmid: 17306702
references.citation: Int J Cardiol. 2009 Aug 14;136(2):178-85
references.pmid: 18644638
references.citation: Lancet. 2004 Jul 10-16;364(9429):141-8
references.pmid: 15246726
references.citation: Blood. 2007 Aug 15;110(4):1362-9
references.pmid: 17483296
references.citation: Rev Esp Cardiol. 2007 Apr;60(4):357-65
references.pmid: 17521544
references.citation: Nat Clin Pract Cardiovasc Med. 2006 Mar;3 Suppl 1:S52-6
references.pmid: 16501632
references.citation: Cardiology. 2000;93(3):168-74
references.pmid: 10965088
references.citation: Eur Heart J. 2006 Dec;27(23):2775-83
references.pmid: 17098754
references.citation: N Engl J Med. 2006 Sep 21;355(12):1210-21
references.pmid: 16990384
references.citation: Nat Med. 2003 Sep;9(9):1195-201
references.pmid: 12910262